Neural Therapeutics Inc.
NURL
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -110.32% | 33.72% | 29.42% | 38.93% | 43.47% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 800.72% | 116.93% | 133.38% | 524.39% | -174.39% |
| Change in Net Operating Assets | 19.91% | -9.38% | 25.53% | -47.24% | -51.24% |
| Cash from Operations | 27.89% | 81.47% | 88.93% | 40.22% | -23.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 137.77% | -1.94% | -89.88% | -50.93% | -29.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | 70.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -223.53% | 100.00% | 100.00% | -- | -101.25% |
| Cash from Financing | 279.10% | 20.47% | -105.68% | -73.99% | -37.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.00% | 9,781.25% | -237.13% | -101.32% | -136.94% |